The Food and Drug Administration last week approved the anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots in patients with atrial fibrillation that is not caused by a heart valve problem. Eliquis is manufactured by Bristol-Myers Squibb, and marketed by BMS and Pfizer.
Mylan announced that its subsidiary, Mylan Pharmaceuticals, has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug applications for rizatriptan benzoate orally disintegrating tablets and rizatriptan benzoate tablets, generic versions of Merck's Maxalt MLT Tablets and Maxalt Tablets.
To meet growing consumer demand for healthier choices, Whole Foods Market is introducing Engine 2 Plant-Strong products, a new line of plant-based, minimally processed snacks, breakfast items and pantry staples.
While the "fiscal cliff" bill heads off the most severe tax implications for most Americans, the 25.8 million Americans with diabetes may find this bill a bitter pill to swallow, suggested the National Community Pharmacists Association in a press release.
DevaCurl — a hair care brand designed exclusively for curly, wavy and chemically processed hair — has created the DevaCurl No-Comb Detangling Spray to untangle, fortify and revitalize dry, damaged and frizz-prone curls while restoring moisture balance.
Emergent BioSolutions announced that it has signed a license agreement with VaxInnate Corporation under which Emergent acquired the exclusive right to manufacture and sell VaxInnate’s pandemic influenza vaccine candidate in the United States.